Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
|
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review
    Jordan, Colleen G.
    Kennalley, Amy L.
    Roberts, Alivia L.
    Nemes, Kaitlyn M.
    Dolma, Tenzing
    Piper, Brian J.
    PHARMACY, 2022, 10 (03)
  • [2] Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature
    Juliana I. Byanyima
    Xinyi Li
    Sianneh A. Vesslee
    Henry R. Kranzler
    Zhenhao Shi
    Corinde E. Wiers
    Current Addiction Reports, 2023, 10 : 581 - 593
  • [3] Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature
    Byanyima, Juliana I.
    Li, Xinyi
    Vesslee, Sianneh A.
    Kranzler, Henry R.
    Shi, Zhenhao
    Wiers, Corinde E.
    CURRENT ADDICTION REPORTS, 2023, 10 (03) : 581 - 593
  • [4] Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review
    Amber N. Edinoff
    Saveen Sall
    Scott P. Beckman
    Andrew D. Koepnick
    Logan C. Gold
    Eric D. Jackson
    Danielle M. Wenger
    Elyse M. Cornett
    Kevin S. Murnane
    Adam M. Kaye
    Alan D. Kaye
    Pain and Therapy, 2023, 12 : 1121 - 1134
  • [5] Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review
    Edinoff, Amber N.
    Sall, Saveen
    Beckman, Scott P.
    Koepnick, Andrew D.
    Gold, Logan C.
    Jackson, Eric D.
    Wenger, Danielle M.
    Cornett, Elyse M.
    Murnane, Kevin S.
    Kaye, Adam M.
    Kaye, Alan D.
    PAIN AND THERAPY, 2023, 12 (05) : 1121 - 1134
  • [6] Discriminative Stimulus and Low Abuse Liability Effects of Novel Endomorphin Analogs Suggest a Potential Treatment Indication for Opioid Use Disorder
    Nilges, Mark R.
    Laurent, Morgan
    Cable, Chloe
    Arens, Louis
    Vafiades, James
    Zadina, James E.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03): : 369 - 379
  • [7] Pharmacists' role in buprenorphine management for opioid use disorder: A narrative review
    Cleary, Jacqueline
    Engle, Amanda
    Winans, Amanda
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2022, 5 (02): : 228 - 238
  • [8] Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting
    Kohan, Lynn
    Barreveld, Antje
    Potru, Sudheer
    Abd-Elsayed, Alaa
    Viscusi, Eugene R.
    PAIN PRACTICE, 2025, 25 (01)
  • [9] Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks
    Camenga, Deepa R.
    Colon-Rivera, Hector A.
    Muvvala, Srinivas B.
    JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2019, 80 (04) : 393 - 402
  • [10] Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
    Hornick, Mary G.
    Stefanski, Ashley
    FRONTIERS IN PHARMACOLOGY, 2023, 14